Rearranged Ig heavy chain DNA is detectable in cell-free blood samples of patients with B-cell neoplasia

Blood

Volumn 90, Issue 12, 1997, Pages 4953-4960

  Frickhofen, N ^a,b   Muller E ^a   Sandherr, M ^a   Binder, T ^a   Bangerter, M ^a   Wiest, C ^a   Enz, M ^a   Heimpel, H ^a  

^a UNIVERSITY OF ULM   (Germany)

^b DR HORST SCHMIDT KLINIKEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; DAUNORUBICIN; DNA; DOXORUBICIN; EDETIC ACID; IMMUNOGLOBULIN HEAVY CHAIN; PREDNISOLONE; PREDNISONE; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; B CELL LEUKEMIA; B CELL LYMPHOMA; BLOOD SAMPLING; CELL FREE SYSTEM; CONTROLLED STUDY; GENE REARRANGEMENT; HUMAN; HUMAN TISSUE; IMMUNOGLOBULIN GENE; MAJOR CLINICAL STUDY; NONHODGKIN LYMPHOMA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL;

EID: 2642692705     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v90.12.4953.4953_4953_4960     Document Type: Article

References (40)

1. Hoelzer D: Treatment of acute lymphoblastic leukemia. Semin Hematol 31:1, 1994
2. Armitage JO: Treatment of non-Hodgkin's lymphoma. N Engl J Med 328:1023, 1993
3. Shipp M, Harrington D, Anderson J, Armitage J, Bonadonna G, Brittinger G, Cabanillas F, Canellos G, Coiffier B, Connors J, Cowan R, Crowther D, Engelhard M, Fisher R, Gisselbrecht C, Horning S, Lepage E, Lister A, Meerwaldt J, Montserrat E, Nissen N, Oken M, Peterson B, Tondini C, Velasquez W, Yeap B: Development of a predictive model for aggressive lymphoma: The international NHL prognostic factors project. N Engl J Med 329:987, 1993
4. Hoelzer D, Thiel E, Loeffler H, Büchner T, Ganser A, Heil G, Koch P, Freund M, Diedrich H, Rühl H, Maschmeyer G, Lipp T, Nowrousian MR, Burkert M, Gerecke D, Pralle H, Müller U, Lunscken C, Fülle H, Ho AD, Küchler R, Busch FW, Schneider W, Goerg C, Emmerich B, Braumann D, Vaupel HA, von Paleske A, Bartels H, Neiss A, Messerer D: Prognostic factors in a multicenter study for treatment of acute lymphoblastic leukemia in adults. Blood 71:123, 1988
5. Coiffier B, Bryon PA, Berger F, Archimbaud E, Ffrench M, Extra J-M, Guyotat D, Fiere D, Gentilhomme O, Magaud J-P, Blanc M, Peaud P-Y, Vuvan H, Viala J-J: Intensive and sequential combination chemotherapy for aggressive malignant lymphomas (protocol LNH-80). J Clin Oncol 4:147, 1986
6. Armitage JO, Weisenburger DD, Hutchins M, Moravec DF, Dowling M, Sorensen S, Mailliard J, Okerbloom J, Johnson PS, Howe D, Bascom GK, Casey J, Linder J, Purtilo DT: Chemotherapy for diffuse large-cell lymphoma. Rapidly responding patients have more durable remissions. J Clin Oncol 4:160, 1986
7. Verdonck LF, van Putten WLJ, Hagenbeek A, Schouten HC, Sonneveld P, van Imhoff GW, Kluin-Nelemans HC, Raemaekers JMM, van Oers RHJ, Haak HL, Schots R, Dekker AW, de Gast GC, Loewenberg B: Comparison of CHOP chemotherapy with autologous bone marrow transplantation for slowly responding patients with aggressive non-Hodgkin's lymphoma. N Engl J Med 332:1045, 1995
8. Canellos GP: Residual mass in lymphoma may not be residual disease. J Clin Oncol 6:931, 1988
9. Surbonne A, Longo DL, DeVita VT, Inde DC, Duffey PL, Jaffe ES, Solomon D, Hubbard SM, Young RC: Residual abdominal masses in aggressive non-Hodgkin's lymphoma after combination chemotherapy: Significance and management. J Clin Oncol 6:1832, 1988
10. Yamada M, Wasserman R, Lange B, Reichard BA, Womer RB, Rovera G: Minimal residual disease in childhood B-lineage lymphoblastic leukemia. Persistence of leukemic cells during the first 18 months of treatment. N Engl J Med 323:448, 1990
11. Yokota S, Hansen-Hagge TE, Ludwig W-D, Reiter A, Raghavachar A, Kleihauer E, Bartram CR: Use of polymerase chain reactions to monitor minimal residual disease in acute lymphoblastic leukemia patients. Blood 77:331, 1991
12. Biondi A, Yokota S, Hansen-Hagge TE, Rossi V, Giudici G, Maglia O, Basso G, Tell C, Masera G, Bartram CR: Minimal residual disease in childhood acute lymphoblastic leukemia: Analysis of patients in continuous complete remission or with consecutive relapse. Leukemia 6:282, 1992
13. Nizet Y, Van Daele S, Lewalle P, Vaerman JL, Philippe M, Vermylen C, Cornu G, Ferrant A, Michaux JL, Martiat P: Long-term follow-up of residual disease in acute lymphoblastic leukemia patients in complete remission using clonogenic IgH probes and the polymerase chain reaction. Blood 82:1618, 1993
14. Potter MN, Steward CG, Oakhill A: The significance of detection of minimal residual disease in childhood acute lymphoblastic leukaemia. Br J Haematol 83:412, 1993
15. Brisco MJ, Condon J, Hughes E, Neoh SH, Sykes PJ, Seshadri R, Toogood I, Waters K, Tauro G, Ekert H, Morley AA: Outcome prediction in childhood acute lymphoblastic leukaemia by molecular quantification of residual disease at the end of induction. Lancet 343:196, 1994
16. Potter MN, Cross NC, van Dongen JJ, Saglio G, Oakhill A, Bartram CR, Goldman JM: Molecular evidence of minimal residual disease after treatment for leukaemia and lymphoma: An updated meeting report and review. Leukemia 7:1302, 1993
17. Price CG, Meerabux J, Murtagh S, Cotter FE, Rohatiner AZ, Young BD, Lister TA: The significance of circulating cells carrying t(14:18) in long term remission from follicular lymphoma. J Clin Oncol 9:1527, 1991
18. Gribben JG, Neuberg D, Freedman AS, Gimmi CD, Pesek KW, Barber M, Saporito L, Woo SD, Coral F, Spector N, Rabinowe SN, Grossbard ML, Ritz J, Nadler LM: Detection by polymerase chain reaction of residual cells with the bcl-2 translocation is associated with increased risk of relapse after autologous bone marrow transplantation for B-cell lymphoma. Blood 81:3449, 1993
19. Finke J, Slanina J, Lange W, Doelken G: Persistence of circulating t(14:18)-positive cells in long-term remission after radiation therapy for localized-stage follicular lymphoma. J Clin Oncol 9:1668, 1993
20. Hardingham JE, Kotasek D, Sage RE, Gooley LT, Mi J-X, Dobrovic A, Norman JE, Bolton AE, Dale BM: Significance of molecular marker-positive cells after autologous peripheral blood stem-cell transplantation for non-Hodgkin's lymphoma. J Clin Oncol 13:1073, 1995
21. Gribben JG, Neuberg D, Barber M, Moore J, Pesek KW, Freedman AS, Nadler LM: Detection of residual lymphoma cells by polymerase chain reaction in peripheral blood is significantly less predictive for relapse than detection in bone marrow. Blood 83:3800, 1994
22. Frickhofen N, Müller E, Wiest C, Bangerter M, Binder T, Heimpel H: Circulating clonotypic DNA in patients with malignant B cell disorders for monitoring response to treatment. Ann Hematol 67:35, 1995 (abstr)
23. Thomas SM, Moreno RF, Tilzer LL: DNA extraction with organic solvents in gel barrier tubes. Nucleic Acids Res 17:5411, 1989
24. Jonsson OG, Kitchens RL, Scott FC, Smith RG: Detection of minimal residual disease in acute lymphoblastic leukemia using immunoglobulin hypervariable region specific oligonucleotide probes. Blood 76:2072, 1990
25. Kneba M, Eick S, Herbst H, Willigeroth S, Pott C, Bolz I, Bergholz M, Neumann C, Stein H, Krieger G: Frequency and structure of t(14;18) major breakpoint regions in non Hodgkin lymphomas typed according to the Kiel classification: Analysis by direct sequencing. Cancer Res 52:3243, 1991
26. Saiki RK, Gelfland DH, Stoffel S, Schaarf SJ, Higuchi R, Horn GT, Mullis KB, Erlich HA: Primer-directed enzymatic amplification of DNA with thermostable DNA polymerase. Science 249:487, 1988
27. Martin M, Carrngton M, Mann D: A method for using serum or plasma as a source of DNA for HLA typing. Human Immunol 33:108, 1992
28. Fowke KR, Plummer FA, Simonsen JN: Genetic analysis of human-DNA recovered from minute amounts of serum or plasma. J Immunol Meth 180:45, 1995
29. Stroun M, Anker P, Lyautey J, Lederrey C, Maurice P: Isolation and characterization of DNA from the plasma of cancer patients. Eur J Clin Oncol 23:707, 1987
30. Chen XQ, Stroun M, Magnenat J-L, Nicod LP, Kurt A-M, Lyautey J, Lederrey C, Anker P: Microsatellite alterations in plasma DNA of small cell lung cancer patients. Nat Med 2:1033, 1996
31. Nawroz H, Koch W, Anker P, Stroun M, Sidransky D: Microsatellite alterations in serum DNA of head and neck cancer patients. Nat Med 2:1035, 1996
32. Chan WC, Wu GQ, Greiner TC, Vose JM, Sharp JG: Detection of tumor contamination of peripheral stem cells in patients with lymphoma using cell culture and polymerase chain reaction technology. J Hematother 3:175, 1994
33. Sidransky D, von Eschenbach A, Tsai YC, Jones P, Summerhayes I, Marshall F, Paul M, Green P, Hamilton SR, Frost P, Vogelstein B: Identification of p53 gene mutations in bladder cancers and urine samples. Science 252:706, 1991
34. Tada M, Omata M, Kawai S, Saisho H, Ohto M, Saiki RK, Sninsky JJ: Detection of ras gene mutations in pancreatic juice and peripheral blood of patients with pancreatic adenocarcinoma. Cancer Res 53:2472, 1993
35. Sidransky D, Tokino T, Hamilton SR, Kinzler KW, Levin B, Frost P, Vogelstein B: Identification of ras oncogene mutations in the stool of patients with curable colorectal tumors. Science 256:102, 1992
36. Sidransky D: Molecular screening - How long can we afford to wait? J Natl Cancer Inst 86:955, 1994
37. Wolff JA, Malone RW, Williams P, Chong W, Acsadi G, Jani A, Felgner PL: Direct gene transfer into mouse muscle in vivo. Science 247:1465, 1990
38. Kwak LW, Campbell MJ, Czerwinski DK, Hart S, Miller RA, Levy R: Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors. N Engl J Med 327:1209, 1992
39. Hawkins RE, Zhu D, Ovecka M, Winter G, Hamblin TJ, Long A, Stevenson FK: Idiotypic vaccination against human B-cell lymphoma: Rescue of variable region gene sequences from biopsy material for assembly as single-chain Fv personal vaccines. Blood 83:3279, 1994
40. Syrengelas AD, Chen TT, Levy R: DNA immunization induces protective immunity against B-cell lymphoma. Nat Med 2:1038, 1996